ライフサイエンスコーパス: type II collagen

1 Arthritis was induced by immunization with type II collagen.

2 s induced in DBA/1 mice by immunization with type II collagen.

3 ed T and B cell autoimmune responses against type II collagen.

4 anism of ceramide-induced down-regulation of type II collagen.

5 lopment of a humoral immune response against type II collagen.

6 ster gene Sox9 and matrix genes aggrecan and type II collagen.

7 s and analysis of T- and B-cell responses to type II collagen.

8 ggrecan may also have a protective effect on type II collagen.

9 rticular chondrocytes after stimulation with type II collagen.

10 mice ages 6-8 weeks old were immunized with type II collagen.

11 ells that coexpressed beta-galactosidase and type II collagen.

12 inity of the denatured protein compared with type II collagen.

13 ific genes and proteins such as aggrecan and type II collagen.

14 s to express the genes encoding aggrecan and type II collagen.

15 COL2A1 identified a novel G118R mutation in type II collagen.

16 the chondrocyte-specific genes aggrecan and type II collagen.

17 ammatory cytokine, IFN-gamma, in response to type II collagen.

18 ) and a fourfold increase in the exposure of type II collagen.

19 the chondrocyte markers Sox9, aggrecan, and type II collagen.

20 ar matrix rich in sulfated proteoglycans and type II collagen.

21 h node cells in vitro after stimulation with type II collagen.

22 e in arthritis induced by antibodies against type II collagen.

23 ersensitivity, and antibody responses to rat type II collagen.

24 of Th2 type cytokines upon immunization with type II collagen.

25 ed by higher amounts of BclII in response to type II collagen.

26 ice against developing arthritis with bovine type II collagen.

27 en they are immunized with porcine and human type II collagen.

28 ss-links at this locus was also confirmed in type II collagen.

29 uced to basal levels and a decreased loss of type II collagen.

30 ve transfer of monoclonal antibodies against type II collagen.

31 associated with a marked reduction in Abs to type II collagen.

32 after induction of CIA by immunization with type II collagen.

33 radation due to its specificity for cleaving type II collagen.

34 isplay arthritis following immunization with type II collagen.

35 groups tested and stained more intensely for type II collagen.

36 enerate cartilage-like structures containing type II collagen.

37 d MKK-6(-/-) mice were immunized with bovine type II collagen.

38 undly suppressed CIA and immune responses to type II collagen.

39 for the chondrocyte-lineage markers Sox9 and type II collagen.

40 de cells from MKK-6(-/-) mice in response to type II collagen.

41 the tissue to helical cross-linking sites in type II collagen.

42 of certain types of collagen, in particular type II collagen.

43 -linked polymers extensively cross-linked to type II collagen.

44 ed this approach in an arthritis model using type II collagen.

45 el of C-terminal crosslinking telopeptide of type II collagen, a cartilage degradation marker associa

46 einase-1, a degradative enzyme that destroys type II collagen, a major architectural component of art

47 Proteolytic fragments of type II collagen, a major component of joint tissue, hav

48 Surprisingly, anti-type II collagen Abs alone did not accumulate in the dis

49 ted lower serum concentrations of IL-6, anti-type II collagen Abs, and total IgG2a.

50 and significantly decreased IgG2a anti-mouse type II collagen Abs.

51 6 months of age contained reduced levels of type II collagen, aggrecan, and glycosaminoglycan compar

52 Ps) as well as matrix repair genes including type II collagen, aggrecan, and HA synthase 2.

53 , MMP-13, and ADAMTS-4 also increased, while type II collagen alpha1 (COL2A1) and aggrecan were down-

54 tion reduced the mRNA levels of aggrecan and type II collagen, although it increased those of MMP1 an

55 Because type II collagen and aggrecan are major functional compo

56 ;Smad3(fl/fl) mice was severely deficient in type II collagen and aggrecan protein due to excessive M

57 ge integrity by regulating the expression of type II collagen and aggrecan, and mutations linked with

58 onsible for cartilage mechanical properties, type II collagen and aggrecan, are degraded in osteoarth

59 s of the cartilage-specific matrix molecules type II collagen and aggrecan, in part via activation of

60 on of chondrogenesis increased expression of type II collagen and aggrecan, whereas it repressed that

61 tant down-regulation of matrix genes such as type II collagen and aggrecan.

62 of stretch with respect to the expression of type II collagen and aggrecan.

63 ts of the cartilage extracellular matrix are type II collagen and aggrecan.

64 ontaining the domains for helical peptide of type II collagen and C-telopeptide of type II collagen,

65 induced in DBA/1J mice by immunization with type II collagen and Freund's complete adjuvant.

66 ytes where it regulates the transcription of type II collagen and in testes where it plays a role in

67 ted by high levels of glycosaminoglycans and type II collagen and low levels of type I and type X col

68 tro studies with immune complexes containing type II collagen and mAb to CII showed that CR2-fH speci

69 Staining for type II collagen and proteoglycan revealed that cartilag

70 for analysis of matrix components, including type II collagen and proteoglycans, and for TIMP-1 produ

71 n OA cartilage and chondrocytes and degrades type II collagen and proteoglycans.

72 leted mutant annexin V that does not bind to type II collagen and shows reduced Ca(2+) channel activi

73 had the highest gene expression of not only type II collagen and SOX9 but also type X collagen, sugg

74 anges in the timing and localization of both type II collagen and Sox9 expression, suggestive of an a

75 CA Akt also promoted type II collagen and Sox9 expression, whereas tBHP treat

76 DBA/1 mice were immunized with bovine type II collagen and then treated with murine IL-21 rece

77 esulting in the surface exposure of "sticky" type II collagen and thus predisposing the vitreous coll

78 nucleus pulposus was heavily cross-linked to type II collagen and to other molecules of type IX colla

79 Male DBA/1 mice were immunized with type II collagen and treated from an early or establishe

80 he expression of specific cartilage markers (Type II Collagen and Type X Collagen), as well as cartil

81 rix proteins (aggrecan, type I collagen, and type II collagen) and enzymes (matrix metalloproteinases

82 drodysplasias (COL2A1 encoding the chains of Type II collagen), and vascular Ehlers-Danlos syndrome (

83 sions of matrix metalloproteinase 3 (MMP-3), type II collagen, and cartilage oligomeric matrix protei

84 showed that the expression levels of MMP-3, type II collagen, and COMP messenger RNA, which are tigh

85 DBA/1J mice were immunized with type II collagen, and in some cases, lipopolysaccharide

86 Transcription levels for aggrecan, type II collagen, and link protein were up-regulated app

87 s induced in DBA/1 mice by immunization with type II collagen, and mice were treated intraperitoneall

88 cartilage oligomeric matrix protein (COMP), type II collagen, and Sox9, whereas anti-miR-199a(*) inc

89 lloproteinase 3 (MMP-3) and MMP-13, degraded type II collagen, and the discoidin domain receptor 2 (D

90 ed by double immunofluorescence of GFPs with type II collagen, and the expression of related factors

91 stern blotting for ERK-1/2, SOX9, c-Fos, and type II collagen, and the level of c-fos messenger RNA (

92 4-deficient mice were immunized with chicken type II collagen, and the onset and severity of CIA were

93 Type II collagen- and cartilage-protective effects exhib

94 (ESR), C-reactive protein (CRP) levels, anti-type II collagen (anti-CII) antibodies, and urinary type

95 /-) and wild-type mice by administering anti-type II collagen antibodies.

96 (CAIA) was generated by injection of an anti-type II collagen antibody cocktail.

97 irst time that only B-cell reduction but not type II collagen antibody levels correlate with the prev

98 arthritis in the CIA model; (4) depletion of type II collagen antibody levels is not necessary for cl

99 ous in inflamed synovium from mice with anti-type II collagen antibody-induced arthritis versus contr

100 ts of the cartilaginous matrix, aggrecan and type II collagen, are degraded at the end of the differe

101 due to increased exposure of chondrocytes to type II collagen as a result of the decreased amount of

102 ession analysis also revealed high levels of type II collagen as compared to type I collagen and abse

103 by chondrocytes, regulates proliferation and type II collagen assembly.

104 s induced in DBA/1 mice by immunization with type II collagen at the base of the tail.

105 by chondrocytes and decreased expression of type II collagen at the protein level.

106 resent in lamprey cartilage, indicating that type II collagen-based cartilage evolved earlier than pr

107 ancestor had a noncollagenous skeleton, with type II collagen becoming the predominant cartilage matr

108 Levels of antibodies against type II collagen (both allo- and autoantibodies) were me

109 cleavage site neoepitope, TIINE, a marker of type II collagen breakdown in cartilage, to analyze the

110 In parallel, the extent of MMP-13 and type II collagen breakdown products was elevated as a fu

111 ocytes cultured on plates coated with native type II collagen but not on gelatin, and overexpression

112 of MMP-13 when chondrocytes were cultured on type II collagen but not on plastic.

113 owed extensive synthesis of proteoglycan and type II collagen but only low levels of type I collagen.

114 cartilage matrix proteoglycan (aggrecan) and type II collagen by matrix metalloproteinases (MMPs) and

115 B6.DR1 mice were immunized with type II collagen/CFA to induce arthritis and were treate

116 with a brief course of CRB-15 at the time of type II collagen challenge markedly inhibited the incide

117 We used adherent ICs containing bovine type II collagen (CII) and 4 monoclonal antibodies (mAb)

118 gens in synovial fluid and cartilage include type II collagen (CII) and cartilage gp39 (HCgp39).

119 Mice were immunized with type II collagen (CII) and treated with anti-CXCL13 or c

120 Anti-type II collagen (CII) antibodies are found in RA patien

121 DBA/1J mice were immunized with bovine type II collagen (CII) at days 0 and 21, and serum was c

122 ropeptide of type II collagen (CPII), to the type II collagen (CII) collagenase-generated cleavage ne

123 artilage proteoglycan aggrecan (PG) or human type II collagen (CII) emulsified with Freund's complete

124 T)] mice received an immunization of chicken type II collagen (CII) in CFA followed by a booster on d

125 B6 mice, and DBA/1 mice were immunized with type II collagen (CII) in Freund's complete adjuvant (CF

126 CIA was induced by injecting DBA/1 mice with type II collagen (CII) in Freund's complete adjuvant, fo

127 ction of 100 microl of an emulsion of bovine type II collagen (CII) in Freund's incomplete adjuvant a

128 ed in DBA/1J mice by the injection of bovine type II collagen (CII) in IFA with added Mycobacterium t

129 in this study that the ectopic expression of type II collagen (CII) in mTECs and the corresponding ce

130 stantiate the involvement of autoimmunity to type II collagen (CII) in the pathogenesis of RA.

131 Type II collagen (CII) is a candidate autoantigen implic

132 Cartilage was analyzed for type II collagen (CII) messenger RNA, C-terminal type II

133 class II elements to bind peptides from the type II collagen (CII) molecule.

134 C57BL/6 mice by i.p. injections of 4 mAb to type II collagen (CII) on day 0 and LPS on day 3.

135 Lubricin concentrations and type II collagen (CII) peptides were quantified by sandw

136 Type II collagen (CII) posttranslationally modified by r

137 DBA/1 mice were immunized with bovine type II collagen (CII) to induce arthritis and then inje

138 ciated alterations to the immune response to type II collagen (CII) were assessed.

139 mph node (LN) cells from mice immunized with type II collagen (CII) were evaluated in vitro.

140 Upon immunization with type II collagen (CII), 85% of NOD.DQ8 mice develop seve

141 s induced in DBA/1 mice by immunization with type II collagen (CII), and before or shortly after immu

142 or 10 generations were immunized with bovine type II collagen (CII), and disease susceptibility and s

143 After immunization with type II collagen (CII), DBA/1(-/-) and B10.DR1(-/-) mice

144 of the immunodominant T cell determinant of type II collagen (CII), i.e., CII(256-276)(N(263), D(266

145 received 2 intradermal injections of bovine type II collagen (CII), on days 0 and 21.

146 -specific CD4(+) T cells and Ab specific for type II collagen (CII), the role of CII-specific T cells

147 ed CD4(+) T cells can present DR4-restricted type II collagen (CII)-derived peptide in vitro, but can

148 mental arthritis and evaluated modulation of type II collagen (CII)-reactive Th cell phenotype as a p

149 sforming growth factor beta1 (TGFbeta1), and type II collagen (CII)-related epitopes (neoepitope from

150 ilage damage; furthermore, the production of type II collagen (CII)-specific antibodies was reduced.

151 Type II collagen (CII)-specific B cell responses have be

152 Although a similar repertoire of type II collagen (CII)-specific TCR-BV8 and BV14-express

153 of human cartilage gp-39 (HC gp-39) or human type II collagen (CII).

154 n emulsion of complete Freund's adjuvant and type II collagen (CII).

155 or were restimulated in culture with BiP or type II collagen (CII).

156 ansgenic littermates after immunization with type II collagen (CII).

157 1J mice after immunization with heterologous type II collagen (CII).

158 HA1) from influenza virus (A/Texas/1/77) and type II collagen (CII).

159 de analogous to the sequence of a segment of type II collagen (CII245-270) but with substitutions at

160 Instead, there is an increase in type II collagen cleavage.

161 ulate collagen synthesis, culturing cells on type II collagen-coated dishes, or overexpression of ful

162 ndrogenically differentiated and purified by type II collagen (Col2)-driven green fluorescent protein

163 of the TGF-beta type II receptor (Tgfbr2) in Type II Collagen (Col2a) expressing cells results in def

164 erentiation by controlling the expression of type II collagen (Col2a1) and aggrecan.

165 yseal dysplasias, are linked to mutations in type II collagen (COL2A1), but the causative gene in SEM

166 n of other chondrocyte marker genes, such as type II collagen (Col2a1), PTH/PTHrP receptor (Pth1r) an

167 retinoic acid-sensitive protein (cd-rap) and type II collagen (COL2A1); this mechanism of repression

168 Here we report that lampreys have two type II collagen (Col2alpha1) genes that are expressed d

169 , cartilage matrix consists predominantly of type II collagen (Col2alpha1), whereas that of jawless f

170 ly - significantly upregulated expression of type II collagen, compared to type-I and pure type-II sc

171 levels of pathogenic autoantibodies against type II collagen, compared with DA rats.

172 That is, with TFP, Low density increases type II collagen content by over 100%, tensile stiffness

173 en (CIIB); antibodies to the C-propeptide of type II collagen (CPII), to the type II collagen (CII) c

174 Urinary C-telopeptide of type II collagen (CTX-II) levels were measured on days 3

175 njury, and urinary C-terminal telopeptide of type II collagen (CTX-II) levels were measured.

176 ated Pyr (Glc-Gal-Pyr), and C-telopeptide of type II collagen (CTX-II) was assessed in urine samples.

177 Upon immunization with type II collagen, DBA/1 mice develop severe articular in

178 concentrated lubricin following ACLT reduces type II collagen degradation and improves weight bearing

179 LT was evident, combined with a reduction in type II collagen degradation.

180 S100A4 stimulates MMP-13 production, a major type II collagen-degrading enzyme, via activation of rec

181 tivity was measured as glycosaminoglycan and type II collagen deposition in pellet cultures.

182 DQB1*0604/DQA1*0103 presented type II collagen-derived peptides that were not presente

183 he immunodominant peptide of the autoantigen type II collagen (DR1-CII), naive T cells were engineere

184 s from DQ8.CD28(-/-) mice did not respond to type II collagen efficiently in vitro, although the resp

185 MMP-8 and MT1-MMP, in that MMP-13 hydrolyzes type II collagen efficiently, whereas MMP-8 and MT1-MMP

186 Using mice lacking neurofibromin 1 (Nf1) in type II collagen-expressing cells, (Nf1col2(-/-) mutant

187 has been initiated, as evidenced by Sox9 and type II collagen expression and extracellular matrix dep

188 with BMP2-induced expression of aggrecan and type II collagen expression and knockdown of Twist1 augm

189 chondrogenesis, leading to reduced Sox-9 and type II collagen expression and less glycosaminoglycan a

190 matrix synthesis and degradation by inducing type II collagen expression and repressing Runx2-inducib

191 Type II collagen expression, which was down-regulated by

192 P with thrombospondin motifs (ADAMTS)-4, and type II collagen expression.

193 f Twist1 augmented BMP2-induced aggrecan and type II collagen expression.

194 ostaining for DDR-2, MMP-13, and MMP-derived type II collagen fragments was detected in cartilage fro

195 talloproteinase 13 (MMP-13), and MMP-derived type II collagen fragments was visualized immunohistoche

196 This protocol involves purification of type II collagen from chicken sternums, immunization of

197 its chondroitin sulfate side-chains, shields type II collagen from exposure on the fibril surface.

198 (IL-1beta) suppresses the expression of the type II collagen gene (COL2A1), associated with inductio

199 Type II collagen gene expression was also significantly

200 ces Col2a1, which encodes cartilage-specific type II collagen gene promoter activity via Sox9.

201 The degradation of type II collagen has been associated with the pathology

202 and intertype cross-linking of the cartilage type II collagen heteropolymer is an integral, early pro

203 digested essential components of cartilage: type II collagen, hyaluronic acid (HA), and glycosaminog

204 he genes for cartilage-specific aggrecan and type II collagen II, as assessed by determination of mes

205 DBA/1 mice were immunized with type II collagen in adjuvant or adjuvant alone, and the

206 ibition of collagenase-mediated breakdown of type II collagen in articular cartilage is unlikely to h

207 SMase down-regulates type II collagen in articular chondrocytes via activatio

208 MP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis

209 mal adult cartilage synthesized little or no type II collagen in contrast to infant and juvenile cart

210 higher levels of autoantibodies against rat type II collagen in DA.F344(Cia5) congenics compared wit

211 Higher levels of type II collagen in human ACV preparations, perhaps medi

212 Type II collagen in human ACVs was of high molecular wei

213 The presence of type II collagen in synthetic cartilage lymph improved b

214 owed a marked reduction of serum IgG against type II collagen, including subclasses IgG1, IgG2a, IgG2

215 cartilage-like ECM rich in proteoglycans and type II collagen, indicative of a stable chondrocyte phe

216 e therapeutic action of tolerogenic DCs in a type II collagen-induced arthritis model and to investig

217 In the type II collagen-induced arthritis model, we observed a

218 2A(q)) mice susceptible to porcine and human type II collagen-induced arthritis.

219 1J pups were given live S. sanguis, CB11, or type II collagen intragastrically.

220 esistant mice, although cellular response to type II collagen is lower in *0402 mice compared with *0

221 Humoral response to type II collagen is not defective in resistant mice, alt

222 Extraction of type II collagen is substantially lower from S1P(cko) ca

223 del, that conjugation of C3d to heterologous type II collagen is sufficient to cause disease in the a

224 Type II collagen is the major cartilage matrix protein i

225 Fibrillar type II collagen is the most prominent component of arti

226 Native type II collagen is tolerogenic when given orally or i.p

227 Type II collagen levels were 100-fold higher in isolated

228 ays in the pathogenesis of experimental anti-type II collagen mAb-passive transfer arthritis.

229 generation induced in vitro by adherent anti-type II collagen mAbs were absent using sera from MASP1/

230 nal candidate 3Hyp substrate sites in the pN type II collagen made by these cells were highly hydroxy

231 ol can be carried out using either type I or type II collagen matrices with primary endothelial cells

232 ajor bone (bone sialoprotein) and cartilage (type II collagen) matrix proteins and in the expression

233 mens, including matrix proteins aggrecan and type II collagen, matrix metalloproteinases MMP13, and A

234 n response to its cartilage-specific ligand, type II collagen, may contribute to cartilage damage in

235 In addition to reduced type II collagen mRNA expression, articular cartilage fr

236 ative of damage and repair, such as elevated type II collagen mRNA, and these levels were not influen

237 ropeptide of type II procollagen (CPII), and type II collagen neoepitope (C2C).

238 collagen (anti-CII) antibodies, and urinary type II collagen neoepitope (uTIINE) levels.

239 quantification of the most abundant urinary type II collagen neoepitope (uTIINE) peptide, a 45-mer w

240 nd decreased biomarkers of type II collagen (type II collagen neoepitope) and aggrecan (peptides endi

241 rix metalloproteinase-generated aggrecan and type II collagen neoepitopes (VDIPEN and C1-2C).

242 oped in our laboratory for the neoepitope of type II collagen (NET2C).

243 heumatoid factor, citrullinated peptide, and type II collagen observed in a novel arthritis model.

244 ced by subcutaneous immunization with bovine type II collagen on day 0 and day 21.

245 Suppression of type II collagen opposed the ability of tRNAi(Met)-overe

246 Ps), at the time of immunization with bovine type II collagen or 3 weeks after immunization.

247 an extracellular matrix protein, but not of type II collagen or aggrecan, two other extracellular ma

248 Moreover, upon stimulation with either type II collagen or gelatin, levels of DDR-2 and MMP-13

249 pe X collagen, but not with type I collagen, type II collagen, or type V collagen.

250 Specific type II collagen peptide biomarkers, including those con

251 d with a candidate RA autoantigen, the human type II collagen peptide CII (259-273).

252 Molecular modeling of type II collagen peptides showed that DQB1*0604/DQA1*010

253 The implanted GFP-BMSCs differentiated into type II collagen-positive cells and reversed cartilage d

254 production by 17% (5% with LIPUS alone), and type II collagen production by 78% (44% by LIPUS alone).

255 cells primed with the tolerogenic epitope of type II collagen proliferated more when incubated with P

256 stems: caBmpr1a was directly driven by a rat type II collagen promoter in a conventional transgenic s

257 Opg transgenic mice were generated by using type II collagen promoter.

258 bited a defective cartilage matrix devoid of type II collagen protein (Col II) and displayed chondrod

259 f TAK1a in articular chondrocytes stimulated type II collagen protein synthesis 3-6-fold and mimicked

260 Type II collagen provides cartilage with its tensile str

261 Treatment with type II collagen-pulsed tolerogenic DCs decreases the pr

262 Treatment of arthritic mice with type II collagen-pulsed tolerogenic DCs, but not unpulse

263 mune response to collagen, recombinant human type II collagen (rCII) was produced using a yeast expre

264 have developed an altered peptide ligand of type II collagen, referred to as A9, which differentiall

265 omal fibroblasts to synthesize and secrete a type II collagen-rich ECM that supports endothelial cell

266 esis of secretome components, resulting in a type II collagen-rich matrix that promotes tumour progre

267 (MT1-MMP), to dissolve and invade type I and type II collagen-rich tissues.

268 Monomeric type-I and type-II collagen scaffolds, which avoid potential immuno

269 Transglutaminase-crosslinked type II collagen showed increased resistance to collagen

270 used transgenic mice whose T cells express a type II collagen-specific receptor (T cell receptor) and

271 than with PAAP(-) Streptococcus gordonii or type II collagen, suggesting an Ag-specific transmucosal

272 ucomatous TM, concomitant with a decrease in type II collagen, suggesting that Cochlin may disrupt th

273 We conclude that type II collagen synthesis in articular cartilage is dow

274 g, induces cartilage degradation and reduces type II collagen synthesis in articular cartilage.

275 into the fibers enhanced cartilage-specific type II collagen synthesis in vitro and in vivo.

276 Expression of Smad3 did not stimulate type II collagen synthesis or enhance that caused by TGF

277 ects were enhanced by TAB1 coexpression, but type II collagen synthesis was not.

278 issue growth factor (CTGF), type I collagen, type II collagen, TGFbeta receptor 1 (TGFbetaR1), and Sm

279 ing articular cartilage, consists largely of type II collagen that matures from a cross-linked hetero

280 dent protease that catalyzes the cleavage of type II collagen, the main structural protein in articul

281 ent protease responsible for the cleavage of type II collagen, the major structural protein of articu

282 In adult mice immunized with type II collagen, these Ag-specific inhibitory T cells m

283 B6.DR1/LAIR-1(-/-) mice were immunized with type II collagen they developed more severe arthritis an

284 Ab responses to heterologous and autologous type II collagen, they are impaired in the ability to ac

285 artilage lesions and decreased biomarkers of type II collagen (type II collagen neoepitope) and aggre

286 to solve the axial, D-periodic structure of type II collagen via multiple isomorphous replacement.

287 Accumulation of type II collagen was also noted within misshapen cartila

288 Remarkably, the expression of aggrecan and type II collagen was detected among all cell types.

289 Type II collagen was quantified by enzyme-linked immunos

290 The synthesis of type II collagen was strongly up-regulated in osteoarthr

291 Chicken type II collagen was used to induce CIA in mice, which w

292 on a glycated lysine-containing peptide from type II collagen, we predicted that similar dihydroxyimi

293 and DDR-2 protein and the amount of degraded type II collagen were higher in the knee joints of Col9a

294 athogenic IgG2a autoantibody levels to mouse type II collagen were increased in mice that received th

295 Significantly higher levels of type II collagen were noted when pericytes undergo chond

296 Reciprocally, telopeptides from type II collagen were recovered cross-linked to helical

297 Next, PAAP(+) S. sanguis and type II collagen were tested for T cell cross-reactivity

298 ng several human cartilage gp39 peptides and type II collagen, were associated with features predicti

299 ide of type II collagen and C-telopeptide of type II collagen, were observed after release by selecte

300 rtilage, due in main part to the cleavage of type II collagen within the matrix by the enzyme matrix